In conclusion, demonstrated the feasibility of identifying EGFR molecular subtypes through the radiomics features of patients with lung adenocarcinoma, making the formulation of clinically individualized targeted therapy programs more precise and more in line with actual clinical needs, so as to benefit the patients with candidate targeted therapy the most. Here, EGFR is linked to lung adenocarcinoma.